combined oral contraceptive IN FEMALE MICE CAUSES HYPERINSULINEMIA DUE TO β-cell HYPERSECRETION AND REDUCTION IN INSULIN CLEARANCE

Publication date: Available online 25 March 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Cremilda Amaral Roso de Oliveira, Thiago dos Reis Araujo, Gésily de Souza Aguiar, Joel Alves da Silva Junior, Jean Franciesco Vettorazzi, Israelle Netto Freitas, Kênia Moreno de Oliveira, Antonio Carlos Boschero, Maria Lúcia Bonfleur, Júlia Rosauro Clarke, Helene Nara Henriques, Rosane Aparecida RibeiroAbstractOral contraception is the most commonly used interventional method in the world. However, several women employ the continuous use of these hormones to avoid pre- and menstruation discomforts. Some studies indicate that oral contraceptives are associated with disturbances in glycemia and the effects of the use of a continuous regime are poorly elucidated. Herein, we evaluated the effects of the continuous administration of a combined oral contraceptive (COC) composed by ethinyl estradiol (EE) and drospirenone (DRSP) on glucose homeostasis in female mice. Adult Swiss mice received 0.6 µg EE and 60 µg DRSP (COC group) or vehicle [control (CTL)] daily by gavage for 35 days. COC treatment had no effect on body weight or adiposity, but increased uterus weight and induced hepatomegaly. Importantly, COC females displayed normal glycemia and glucose tolerance, but hyperinsulinemia and lower plasma C-peptide/insulin ratio, indicating reduced insulin clearance. Furthermore, COC mice displayed reduced protein content of the β subunit of the insulin ...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research